Introduction
Levetiracetam (LEV) is a new generation antiepileptic drug whose efficacy and tolerability in epilepsy treatment is well recognized.
1,2 Synaptic vesicle protein 2A (SV2A), an intracellular protein, is the binding site of levetiracetam in the brain. 3 Several clinical trials reported a clear anticonvulsant effect of LEV but also an increased incidence of pharyngitis and rhinitis in LEV-treated patients. [4] [5] [6] [7] [8] [9] The reason for this latter finding remains unknown. It was reported that white blood cell and neutrophil counts were in the normal range in levetiracetam-treated patients who developed infections 8 but were significantly decreased during treatment compared to the pretreatement status. 9 Similarly, we found interictally no clear effect of LEV on B lymphocytes as well as Seizure 22 (2013) [462] [463] [464] [465] [466] Purpose: To further elucidate possible immune-modulatory effects of valproate (VPA) or levetiracetam (LEV), we investigated their influence on apoptosis and cytotoxic function of CD8 + T lymphocytes in humans.
Methods: In 15 healthy subjects (9 female (60%), 35.7 AE 12.1 years), apoptosis and cytotoxic function of CD8 + T lymphocytes were measured using flow cytometry following in vitro exposure to LEV (5 mg/L and 50 mg/L) and VPA (10 mg/L and 100 mg/L). Apoptosis rates were determined after incubation with LEV or VPA for 1 h or 24 h. Cytotoxic function was assessed following 2 h stimulation with mixed virus peptides, using perforin release, CD107a/b expression and proliferation. on CD4 + and CD8 + T lymphocyte counts in the blood of LEV-treated patients. 10 The primary role of CD8 + T lymphocytes is to protect against viral infections by lysing infected cells via degranulationdependent perforin release which can be measured by increased expression of CD107a and CD107b on the cell surface 11 and secretion of soluble factors, such as interferon-g (IFN-g) and tumor necrosis factor-a (TNFa). [12] [13] [14] [15] Treatment with valproate (VPA) was not found to be associated with a higher infection rate. 16 However, VPA is a potent histone deacetylase (HDAC) inhibitor [17] [18] [19] and histone modification plays a role in the regulation of the effector functions of memory CD8 + T cells. 20 Moreover, VPA can induce apoptosis in various leukemia cells in vivo and in vitro. [17] [18] [19] VPA also influenced postictal blood levels of TNFa and interleukin (IL)-1b as well as CD4 + T cell counts. 21, 22 In this study, we investigated the influence of LEV and VPA on proliferation, apoptosis, CD107 mobilization and perforin release of CD8 + T lymphocytes in vitro in order to better understand their pharmacological effects and adverse events.
Materials and methods

Study population
Fifteen healthy adult volunteers recruited from the staff of the Department of Neurology, University of Marburg (9 female (60%), age: 35.7 AE 12.1 years; range: 18-60 years) were included in the study. None of the volunteers took any medication. Immediately after venous blood drawing (10 mL), the experiments were started. The study was approved by the local ethics committee.
Antibodies, reagents and peptides
We used the following antibodies, reagents and peptides: CD3-APC, CD8-PerCP, perforin-PE, IgG2b 
Anticonvulsant drugs
Levetiracetam (Keppra 1 , UCB Pharma S.A., Brussels, Belgium) and sodium valproate (Ergenyl 1 vial, Sanofi Aventis, Frankfurt, Germany) were dissolved in sterile physiological saline to produce fresh solutions as required. When treating cells, the drugs were further diluted in the culture medium to the final concentrations of 5 mg/L or 50 mg/L for LEV (serum reference range in adults for drug fasting levels: 12-46 mg/L) and 10 mg/L or 100 mg/L for VPA (serum reference range in adults for drug fasting levels: 50-100 mg/L), respectively. 23 
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Biocoll Separating Solution by density gradient centrifugation (1500 rpm, 20 8C, 30 min, without brake) of heparinized blood obtained by venipuncture of the healthy volunteers. Viability of PBMCs obtained was always >95%, as determined by 0.4% trypan blue staining. After double washing in cold PBS, PBMCs were cultured with RPMI 1640 supplemented with 10% heat-inactivated pooled human AB serum and 1% penicillin-streptomycin.
Activation of CD8 + T lymphocytes
In the functional assays, CD8 + T lymphocytes were activated with CTL-CEF-Class I peptide pool ''Plus'', which contains 32 peptides, each corresponding to a defined HLA class I restricted Tcell epitope from cytomegalovirus, Epstein-Barr virus and influenza virus. Most humans have been previously exposed to one or more of these pathogens, respectively. One hundred microliter PBMCs (2-3 Â 10 6 cells/mL) were incubated with 64 mg/mL of CEF peptide (100 mL) at 37 8C in a humidified, 5%
CO 2 incubator for 2 h. Costimulatory antibodies (BD FastImmune TM CD28/CD49d costimulatory reagent) were added according to the manufacturer's protocol. A negative control (only anti-CD28/ CD49d) was included in every experiment.
Perforin release
Perforin release was measured as previously described. 24 After activation of CD8 + T lymphocytes for 2 h either in the presence or absence of anticonvulsant drugs, cells were first stained with CD3-APC and CD8-PerCP for 30 min and were then resuspended in BD Cytofix/Cytoperm solution for 20 min at 4 8C. After washing and centrifugation (1200 rpm, 20 8C, 4 min), cells were labeled with perforin-PE in Perm/Wash buffer solution. IgG2b-PE isotype control was used for negative control. Perforin expression was measured by flow cytometry. The baseline of perforin expression was measured in unstimulated cells immediately after isolation. A reduction in degranulation was indicated by a higher percentage of perforin+ cells remaining after stimulation.
CD107 mobilization
CD8
+ T lymphocyte degranulation can also be measured by increased expression of surface CD107a and CD107b. 11,25 CD107 mobilization was measured as previously described. 30 Briefly, CD107a/b-FITC and monensin (BD GolgiStop, used according to manufacturer's instructions) were added before activation of CD8 + T lymphocytes in the presence or absence of anticonvulsant drugs. After incubation for 2 h, cells were washed and stained with CD3-APC-and CD8-PerCP-antibodies as described above followed by characterization of cells in the flow cytometer. The baseline of CD107a/b expression was measured in unstimulated cells immediately after isolation.
Analysis of CD8 + T lymphocyte proliferation by CFSE labeling
PBMCs were labeled with 0.4 mM CFSE at 37 8C for 10 min in the dark. Free CFSE was quenched with ice-cold culture medium for 5 min. Following two washes, the labeled cells were resuspended in the culture medium. Costimulatory antibodies (CD28/CD49d) and 100 mL of CEF peptides were added into 100 mL of CFSElabeled PBMCs (2-3 Â 10 6 cells/mL) in the presence or absence of anticonvulsant drugs. Recombinant human IL-2 (40 IU/mL) was added at the time of peptide stimulation. The negative control consisted of cultures of CFSE-labeled, unstimulated cells. After incubation in a 5% CO 2 incubator at 37 8C for 5 days, cells were washed with culture medium and cell surfaces were stained with CD3-APC and CD8-PerCP. Cells were analyzed by flow cytometry. The definition for low CFSE cells was defined according to the distribution of CSFE in unstimulated cells. For Western blot analysis, protein was separated on 10% SDS-PAGE gels (Rotiphorese 10Â SDS PAGE, Rotiphorese Gel 30, TRIS HCl, Roth, Karlsruhe, Germany) by electrophoresis. Gels were transferred to nitrocellulose membranes (Invitrogen, Germany) and processed as described for protein assays. Briefly, Roti-Block blocking buffer (Roth, Karlsruhe, Germany) was used for blocking the blots, incubation with the SV2A antibody (1:1000) overnight at 4 8C followed. After washing with PBS/0.05% Tween 20, the blots were incubated for 2 h with HRP-conjugated secondary antibody (1:1000, rabbit anti goat IgG-HRP) at room temperature.
Actin-HRP antibody (Goat anti actin HRP) served as loading control.
Total RNA was isolated from PBMCs with RNeasy Mini Kit (Quiagen Inc.) according to manufacturer's instructions. Total RNA (2 mg) was reverse transcribed with 200 U/mL of Superscipt II Rnase H-Reverese Transcription (Invitrogen), using Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers (Pd(T)12-18: #277858-25UT) according to the manufacturer's instructions.
SV2a mRNA levels were determined by using the Applied Biosystems 7900 HT Thermal Cycler. The amplification protocol consisted of first step at 50 8C for 2 min, a denaturation step at 95 8C for 10 min, followed by 50 cycles with a 95 8C denaturation step for 15 s and 60 8C annealing for 60 s. The following primers were used for specific amplification. PCR products were analyzed by melting curve analysis. A negative control (no template) was measured in each of the PCR runs. The cDNA copy number of SV2a was calculated in relation to the amplification product amount of internal standard.
Apoptosis evaluation
Fresh PBMCs were seeded at 2-3 Â 10 5 cells/well in 96-well plates and LEV (5 mg/L or 50 mg/L) or VPA (10 mg/L or 100 mg/L) was added, respectively. PBMCs without addition of anticonvulsants served as controls. After incubation for 1 h or 24 h at 37 8C in a humidified, 5% CO 2 -air incubator, plates were centrifuged (1200 rpm, 20 8C, 4 min) and supernatants were aspirated. The cells were stained with CD3-APC and CD8-PerCP for 30 min in the dark on ice. Annexin V Apoptosis Detection Kit was used to detect apoptosis. Briefly, after washing with culture medium and centrifugation (1200 rpm, 20 8C, 4 min), the cells were resuspended in 200 mL of Annexin V binding buffer and incubated with 2 mL of Annexin V-FITC and 2 mL of PI for 10 min in the dark at room temperature. Then, Annexin-binding was measured on a four-color flow cytometer (FACSCalibur 1 , CellQuest 1 software, Becton Dickinson).
Statistical analysis
Intra-individual group comparisons were performed with nonparametric Wilcoxon matched-pairs test because Gaussian distribution could not assumed. The data are presented as median values and interquartile ranges (IQR). Because of multiple testing and the explorative nature of the study, the significance level was set to p < 0.01. (Fig. 1). (Fig. 2) . 
Results
Perforin release
CD107a/b expression
Expression of SV2A in human CD8
+ T lymphocytes SV2A could be detected in human CD8 + T lymphocytes by both flow cytometry and Western blot analysis. The rtPCR could verify that mRNA for SV2A exists in PBMCs.
Apoptosis
Spontaneous apoptosis was observed in cells untreated with LEV or VPA after incubation for 1 h and 24 h. In the highconcentration VPA group, the percentage of apoptotic CD8 + T lymphocytes was significantly lower than that in the control group after 24 h of incubation (VPA 100 mg/L vs. control: 7.3% (IQR 5. (Fig. 3) . 
Discussion
The main finding of this study was that LEV had an attenuating effect on degranulation of CD8 + T lymphocytes as indicated by reduced perforin release and decreased CD107a/b mobilization after CEF-peptide stimulation in vitro. SV2A was found to exist in human CD8 + T lymphocytes. Therefore, it can be hypothesized that In clinical studies, LEV treatment increased the incidence of pharyngitis and rhinitis which was associated with a slight but significant drop in white blood cell counts. 9 Similarly, a study on interictal alterations of leukocytes and cytokines in the blood of patients with active epilepsy found a trend toward decreased counts of CD8 + T lymphocytes. 10 While this study did not confirm a significant effect of LEV on apoptosis of CD8 + T lymphocytes in vitro, the results suggest that LEV compromised the function of CD8 + T lymphocytes.
Cytotoxicity of CD8 + T lymphocytes is mainly mediated by release of pre-formed cytolytic granules which contain perforin.
Other less important pathways involve the secretion of soluble cytokines and Fas/FasL interaction. [12] [13] [14] [15] Degranulation can cause positive expression of CD107a/b on the cell surface for a brief period of time before these proteins are internalized again. 26 Therefore, expression of CD107 on CD8 + T cells can be a marker for degranulation. Consequently, expression of CD107 on the cell surface was reduced in this study in the presence of LEV paralleling the reduction in perforin release. This attenuating effect of LEV on perforin release may help explaining the higher rates of pharyngitis/rhinitis in LEV-treated patients. 5 In addition to its immunological effects, perforin plays also a role in blood-brain-barrier (BBB) permeability. Recently, it was reported that CD8 + T lymphocytes can lead to BBB dysfunction through a perforin-dependent process. 27 In recent experiments, Marchi and co-workers found reduced BBB damage in perforindeficient pilocarpine-treated epileptic mice. 28 Inducing BBB disruption may establish a link between the systemic immune system and the brain. [29] [30] [31] [32] This leads to the hypothesis that levetiracetam's attenuating effect on perforin release adds to its anticonvulsant potency via reduction of BBB disruption. Further studies in this field are warranted. The attenuated degranulation of CD8 + T lymphocytes by LEV is probably caused by binding to SV2A, the presence of which we could prove in human CD8 + T lymphocytes. These results are preliminary and because of the limited number of samples future examination is warranted for this respect. But this detection is in line with a recently published study where detection of SV2A mRNA in T lymphocytes of mice could be documented.
33
SV2A was identified as the binding site of LEV in the brain. 3 It has been reported that SV2A exists in a variety of neurons and endocrine cells. [34] [35] [36] [37] In neurons, SV2A is associated with synaptic vesicle fusion, exocytosis and neurotransmitter release. 38 Further studies are required to verify that SV2A inhibition explains the depressive effects of LEV on degranulation of human CD8 + T lymphocytes. This study did not reveal any effects of VPA on degranulation of CD8 + T lymphocytes but could show that 100 mg/L of VPA reduced spontaneous apoptosis of CD8 + T lymphocytes in healthy volunteers. Similarly, it was reported that healthy donor T cells were significantly less sensitive to induction of apoptosis in the presence of VPA than primary chronic lymphocytic leukemia cells. 19 This insensitivity was more prominent for high concentrations of VPA than low concentrations. Valproate was found to induce apoptosis of various leukemia cells in vivo and in vitro contrasting its effects on healthy T cells. [17] [18] [19] Therefore, our results support the view that VPA has antiapoptotic effects.
In conclusion, we could show that LEV had a moderate depressive effect on degranulation of CD8 + T lymphocytes, indicating that LEV can disturb the antiviral function of the immune system. This effect is possibly mediated by SV2A inhibition and may help to explain the increased incidence of upper respiratory tract infections in LEV-treated patients.
